Why the study?
Does the combination of TAK-044 and temocaprilat improve myocardial metabolism and contraction during ischemia and reperfusion in isolated rabbit hearts?
Does the combination of TAK-044 and temocaprilat improve myocardial metabolism and contraction during ischemia and reperfusion in isolated rabbit hearts?
The combination of an endothelin receptor antagonist and an ACE inhibitor synergistically improves myocardial energy metabolism during ischemia and reperfusion in an isolated rabbit heart model, though without immediate improvement in contractility.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dual endothelin-ACE inhibition in myocardial protection; leaves open translation to function or clinical settings.
The effect of an endothelin (ET) A/ETB receptor antagonist, TAK-044, and/or an angiotensin converting enzyme (ACE) inhibitor, temocaprilat, on myocardial metabolism and contraction during ischemia and reperfusion was examined by phosphorus 31-nuclear magnetic resonance (31P-NMR) in Langendorff rabbit hearts. After normothermic 15 min global ischemia, 60min of postischemic reperfusion was carried out. TAK-044 and/or temocaprilat was administered from 40 min prior to the global ischemia. Adenosine triphosphate (ATP), creatine phosphate, inorganic phosphate, pH, left ventricular systolic developed pressure (LVDev.P), left ventricular end-diastolic pressure (LVEDP) and coronary flow were measured. Twenty-eight hearts were divided into 4 experimental groups consisted of seven hearts each: Group I consisted of controls, Group II was perfused with TAK-044 (10(-6) mol/L), Group III was perfused with temocaprilat (10(-6) mol/L), and Group IV was perfused with TAK-044 (10(-6) mol/L) in combination with temocaprilat (10(-6) mol/L). Group II showed a more early recovery of ATP during postischemic reperfusion (82+/-3%) compared with Group I (71+/-3%). Group III showed a significant inhibition of the decrease in ATP during global ischemia (54+/-3%) compared with Group I (45+/-3%). Group IV also showed a significant marked inhibition of the decrease in ATP during global ischemia (59+/-5%) and a more significant improvement on recovery of ATP during postischemic reperfusion (86+/-3%) compared with the other 3 groups. There were no differences in LVDev.P, LVEDP and coronary flow among these groups. In conclusion, TAK-044 in combination with temocaprilat had a significant potentiation on myocardial metabolism during both ischemia and reperfusion.
No takes yet. Share an insight, caveat, or question.
Kawabata et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: